NEU 2000

Drug Profile

NEU 2000

Alternative Names: Neu2000; Neu2000KL

Latest Information Update: 12 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amkor Pharma
  • Developer AmKor Pharma; GNT Pharma
  • Class Benzoic acids; Neuroprotectants; Small molecules
  • Mechanism of Action Antioxidants; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stroke
  • Preclinical Burns
  • No development reported Myocardial infarction; Spinal cord injuries

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Stroke in USA (IV, Infusion)
  • 16 May 2016 The Korea Ministry of Food and Drug Safety approves IND application for Neu 2000 in Stroke
  • 16 May 2016 GNT Pharma plans a phase II trial for Stroke in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top